Substantial doubt about the company's ability to continue as a going concern.
“These matters raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-K filed Sep 25, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Propanc Biopharma received Nasdaq notice of noncompliance with the $1.00 minimum bid price after 30 consecutive business days, with delisting set for November 2, 2026. It plans to appeal by October 30, 2026, believing it has cured the deficiency.
Propanc Biopharma, Inc. registered up to 6,500,000 shares for resale by Hexstone Capital LLC; the company receives no resale proceeds and faces substantial doubt about continuing as a going concern.
Propanc Biopharma reported no revenue, a $18,862,710 net loss and $832,006 cash as of June 30, 2026; its auditor included a “Going Concern Qualification,” as available cash cannot cover obligations over the next 12 months.
